Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
作者
Scott T. Tagawa,Krishnan Ramaswamy,Ahong Huang,Jack Mardekian,Neil M. Schultz,Li Wang,Rickard Sandin,Stanislav Lechpammer,Daniel J. George
Authors and Affiliations Weill Cornell Medicine, New York, NY, USA Scott T. Tagawa Pfizer Inc., New York, NY, USA Krishnan Ramaswamy & Jack Mardekian STATinMED Research, Plano, TX, USA Ahong Huang & Li Wang Astellas Pharma Inc., Northbrook, IL, USA Neil M. Schultz Pfizer AB., Sollentuna, Sweden Rickard Sandin Pfizer Inc., San Francisco, CA, USA Stanislav Lechpammer Duke Cancer Institute, Duke University School of Medicine, Durham, NC, USA Daniel J. George Authors Scott T. Tagawa View author publications You can also search for this author in PubMed Google Scholar Krishnan Ramaswamy View author publications You can also search for this author in PubMed Google Scholar Ahong Huang View author publications You can also search for this author in PubMed Google Scholar Jack Mardekian View author publications You can also search for this author in PubMed Google Scholar Neil M. Schultz View author publications You can also search for this author in PubMed Google Scholar Li Wang View author publications You can also search for this author in PubMed Google Scholar Rickard Sandin View author publications You can also search for this author in PubMed Google Scholar Stanislav Lechpammer View author publications You can also search for this author in PubMed Google Scholar Daniel J. George View author publications You can also search for this author in PubMed Google Scholar Corresponding author Correspondence to Krishnan Ramaswamy .